Trial
NCT00725062
Donor T Cells in Treating Patients With High-Risk Hematologic Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Masonic Cancer Center, University of Minnesota
Collaborators
—
Condition
Graft Versus Host Disease
Intervention
CD4+CD25+ regulatory T cells
Why stopped
Slow accrual.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-11-29